Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $339.8 million.

  • Madrigal Pharmaceuticals' Non-Current Debt rose 19017.14% to $339.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.8 million, marking a year-over-year increase of 19017.14%. This contributed to the annual value of $117.6 million for FY2024, which is 180.9% up from last year.
  • Latest data reveals that Madrigal Pharmaceuticals reported Non-Current Debt of $339.8 million as of Q3 2025, which was up 19017.14% from $118.4 million recorded in Q2 2025.
  • Madrigal Pharmaceuticals' 5-year Non-Current Debt high stood at $339.8 million for Q3 2025, and its period low was $48.7 million during Q2 2022.
  • In the last 4 years, Madrigal Pharmaceuticals' Non-Current Debt had a median value of $115.8 million in 2023 and averaged $114.6 million.
  • Within the past 5 years, the most significant YoY rise in Madrigal Pharmaceuticals' Non-Current Debt was 19017.14% (2025), while the steepest drop was 151.71% (2025).
  • Over the past 4 years, Madrigal Pharmaceuticals' Non-Current Debt (Quarter) stood at $49.3 million in 2022, then skyrocketed by 134.29% to $115.5 million in 2023, then rose by 1.81% to $117.6 million in 2024, then surged by 188.98% to $339.8 million in 2025.
  • Its Non-Current Debt was $339.8 million in Q3 2025, compared to $118.4 million in Q2 2025 and $118.0 million in Q1 2025.